Valproate induced carnitine deficiency and hyperammonaemia
Clinical Medicine · 2023-07 · 23 (4) · 429
DOI: 10.7861/clinmed.let.23.4.1 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Medicine, 2023-07. Verfasst von Eamon P McCarron. Beteiligte Einrichtung: Queen's University Belfast, Belfast, Northern Ireland. Hauptthemen laut MEDLINE: Hyperammonemia, Epilepsy, Amino Acid Metabolism, Inborn Errors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Editor – I read with interest the article by Yu-E et al, [1][1] and the earlier case by Camilleri et al. [2][2] Hyperammonemia is a recognised complication of treatment with valproic acid (VPA) or its sodium salt (sodium valproate) and although the mechanism is not fully understood, secondary
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Queen's University Belfast, Belfast, Northern Ireland.
Zitieren
APA
McCarron, E. P. (2023). Valproate induced carnitine deficiency and hyperammonaemia. Clinical Medicine, 23(4), 429. https://doi.org/10.7861/clinmed.let.23.4.1
Vancouver
McCarron EP. Valproate induced carnitine deficiency and hyperammonaemia. Clinical Medicine. 2023;23(4):429. doi:10.7861/clinmed.let.23.4.1
BibTeX
@article{McCarron2023,
author = {McCarron, Eamon P},
title = {Valproate induced carnitine deficiency and hyperammonaemia},
journal = {Clinical Medicine},
year = {2023},
volume = {23},
number = {4},
pages = {429},
doi = {10.7861/clinmed.let.23.4.1}
}
EUVIMED